Infant Microbiome, Gut Health, Childhood Asthma, Long-Term Health

The Foundation of a Lifetime: How Infant Microbiome Colonization Shapes Long-Term Health

The first microbial communities that colonize an infant’s gut form a biological blueprint for health. For the 245 preterm infants enrolled in the BLOOM study at the University of Calgary, this foundational process is uniquely challenging. The study’s goal is to map how disruptions in early colonization predict childhood outcomes like asthma and neurodevelopmental delays, offering a window into how lifelong health trajectories are set.

Why Preterm Birth Disrupts a Critical Developmental Window

Full-term infants acquire their initial gut microbes primarily during vaginal birth and through breastfeeding, following a relatively predictable sequence. Preterm infants, defined as those born before 37 weeks gestation, miss this window. Their immature immune systems and digestive tracts are not ready to support a stable microbial community. Instead, colonization is driven by exposures in the Neonatal Intensive Care Unit (NICU), including antibiotics, formula feeding, and a sterile environment. The BLOOM study, led by Dr. Marie-Claire Arrieta, hypothesizes that this “incorrect” microbial seeding fails to train the immune system properly, a process linked to how early gut bacteria shape lifelong immunity.

The mechanism is one of missed signals. Beneficial pioneer bacteria like Bifidobacterium, which thrive on human milk oligosaccharides, produce metabolites like short-chain fatty acids. These compounds are not just food for gut cells; they signal to the developing immune system to promote tolerance and reduce inflammatory responses. When antibiotic use or lack of breast milk suppresses these bacteria, the system may default to a state of heightened alert, priming the body for allergic and autoimmune conditions. This disrupted communication may extend to the gut-brain axis, affecting neurodevelopment.

BLOOM’s Comprehensive Approach: From Weekly Stool Samples to Childhood Questionnaires

Initiated in 2019, BLOOM is not a snapshot but a longitudinal movie of microbiome development. Researchers collect maternal stool and weekly infant stool, urine, and human milk samples for the first two months. This intensive phase is critical for capturing the chaotic initial colonization. Follow-ups at 3 months, 1 year, and 3 years “corrected age” (adjusted for prematurity) add layers of context: nasal swabs, hair cortisol for stress measurement, blood, and detailed surveys on diet, medications, and home environment.

By May 2026, the team had enrolled 245 participant families from four Calgary NICUs. An initial analysis of the first 105 infants, published in December 2025, began to characterize these early-life profiles. The study’s power lies in its ability to correlate specific microbial patterns at, say, 4 weeks old with a diagnosis of asthma or a lag in developmental milestones at age 3. It moves beyond association to identify predictive biomarkers. A key limitation, acknowledged by the authors, is that as an observational study, it can identify links but not prove direct causation; that requires future interventional trials.

Translating Research into Future Clinical Practice

The ultimate goal of BLOOM is to create actionable tools for neonatology. One application is risk stratification. By identifying a “high-risk” microbial signature in a preterm infant’s first few weeks, clinicians could flag those who need closer monitoring for respiratory or developmental issues. This is similar to how SIBO diagnosis now incorporates microbiome insights to guide treatment.

More directly, the findings will inform targeted interventions. If certain bacteria from maternal stool or specific components of human milk are consistently linked to better outcomes, they could be developed into next-generation probiotics or nutritional supplements. The research also examines the home environment, which may provide clues about how family diet and lifestyle can support a child’s microbiome after leaving the NICU. These strategies aim to gently steer a disrupted microbial community toward a healthier trajectory.

Frequently Asked Questions

Can the negative effects of a disrupted infant microbiome be reversed later in life?

While the first three years are a critical window for establishing the microbiome, the community remains somewhat plastic throughout life. Interventions like diet, prebiotics, and probiotics can induce changes, but early foundational disruptions may create a lasting predisposition that requires ongoing management.

Does this research apply to full-term infants born via C-section or given antibiotics?

Yes, the principles are similar. Any factor that alters the initial microbial seeding—like C-section delivery or antibiotic exposure—represents a less severe but comparable disruption to the process studied in preterm infants, potentially influencing long-term health risks.

What can parents of preterm infants do now to support gut health?

In consultation with the NICU team, providing human milk is the single most supportive evidence-based practice. Skin-to-skin contact and, when medically safe, minimizing unnecessary antibiotic use are also beneficial strategies supported by current knowledge.

How soon will findings from BLOOM lead to new treatments?

The study is observational and will conclude data collection in the coming years. Its results will first identify clear microbial targets for health. Developing and testing specific probiotic or nutritional interventions based on those targets will then require further clinical trials.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42612036/
https://pubmed.ncbi.nlm.nih.gov/42583000/
https://pubmed.ncbi.nlm.nih.gov/42577959/